Article Link

4. Comparison of Immunogenicity between the Proposed Pegfilgrastim Biosimilar MYL-1401H and Reference Pegfilgrastim

  • Date: Dec 7th, 2017
  • Authors: C Waller, Gopinath M. Ranganna, Eduardo Pennella, Leonard A. Mattano, MD, Chien Chang Loa, Charles Donnelly, Mark Shiyao Liu, Heather Watson, Julien St-Jean, Sanjukta Chatterjee, Vivek Nayak, Nilanjan Sengupta, Mudgal A. Kothekar, Abhijit Barve

Abstract:

Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is indicated for reduction of incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. Here, the immunogenicity data for MYL-1401H, a proposed biosimilar of pegfilgrastim, from the clinical studies will be presented.

 
Related Links

Manufacturing

We have built global scale and world-class capabilities that leverage advanced technologies and an unwavering commitment to quality, to transform...
Read More

Monoclonal Antibodies

Biocon Biologics has a proven track record in the science, scale, scope and complexity of biologics manufacturing. Over the years...
Read More

Connect with us

Subscribe

Our Parent Company

Quick Links

Our Parent Company
Facebook-f Youtube Linkedin-in

© 2025, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree

Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree